Blueprint Medicines’s Ayvakyt Receives EC’s Approval for the Treatment of Adult Patients with Indolent Systemic Mastocytosis (ISM)
Shots:
- Blueprint Medicines has received approval from the EC for Ayvakyt (avapritinib) to treat adult patients with indolent systemic mastocytosis (ISM)
- Following a positive opinion from the CHMP, the EC approved Ayvakyt based on data from the study (PIONEER) which demonstrated significant improvements compared to PBO in 1EP & 2EP, addressing overall symptoms & mast cell burden along with favorable safety profile
- Ayvakyt, a kinase inhibitor designed to potently and selectively target KIT D816V that is already approved by EC for ISM, adults with ASM, SM-AHN/MCL/GIST
Ref: Blueprint Medicines | Image: Blueprint Medicines
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
